New cancer treatment using extended half-life GlyTR1 with immune checkpoint inhibitors
Official title: Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
Funded at Glytr Therapeutics, INC. · NIH-11159869 · Data updated 2026-11-12
This study is exploring a new way to help people with hard-to-treat cancers by using a special treatment that combines a new type of immune therapy with existing cancer treatments, aiming to better target and attack cancer cells for those who have limited options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glytr Therapeutics, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project start | September 21, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $908,910 |
| NIH project number | 4R42CA285234-02 |
| Project ID | NIH-11159869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with non-resectable recurrent or metastatic solid cancers who have exhausted other treatment options.
✕Less likely to help
Patients with early-stage cancers or those who have not yet undergone other treatment modalities may not benefit from this research.
What this research studies
This research investigates a novel approach to treating non-resectable recurrent or metastatic solid cancers by combining extended half-life GlyTR1 with immune checkpoint blockade therapies. The focus is on developing antigen-targeting cancer immunotherapies, particularly bi-specific antibodies, which can engage the immune system to attack cancer cells more effectively. The study aims to identify safe antigen-specific immunotherapies that can be used for patients with limited treatment options, especially those with solid tumors that express unique carbohydrate antigens. By targeting these specific antigens, the research hopes to improve treatment outcomes for patients with aggressive cancers.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with difficult-to-treat solid tumors.
How similar studies have gone: Other research has shown promise in using bi-specific antibodies for cancer treatment, indicating that this approach has potential based on previous successes.
Where this research is happening
-
Glytr Therapeutics, INC.
San Carlos, United States Active
Researchers
- Principal investigator: Demetriou, Michael — Glytr Therapeutics, INC.
- Study coordinator: Demetriou, Michael
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.